Lymphoma in Dogs: Types, Treatment Options, and Prognosis
Lymphoma is one of the most common cancers diagnosed in dogs, representing somewhere between 7 and 24% of all canine malignancies depending on the population studied. It arises from lymphocytes — the white blood cells central to immune function — and can affect virtually any organ in the body since lymphoid tissue is found throughout the entire system. Understanding the different forms of lymphoma, what treatment involves, and what owners can realistically expect helps make an overwhelming situation more manageable.
The Different Forms of Canine Lymphoma
Lymphoma in dogs is not a single disease but a group of related cancers, classified by anatomical location and by the type of lymphocyte involved. The anatomical classification system includes four main forms.
- Multicentric lymphoma accounts for roughly 80 to 85% of cases and involves multiple lymph node groups simultaneously. It is the form most people picture when they think of lymphoma in dogs.
- Alimentary (gastrointestinal) lymphoma affects the digestive tract and typically causes vomiting, diarrhoea, weight loss, and reduced appetite. It is the second most common form.
- Mediastinal lymphoma involves lymphoid structures within the chest cavity, particularly the thymus and mediastinal lymph nodes, and commonly presents with breathing difficulties and regurgitation.
- Extranodal lymphoma refers to disease arising in unusual locations such as the skin, eyes, kidneys, or nervous system, and each location brings its own specific set of clinical signs.
Immunophenotyping — determining whether the cancer originates from B lymphocytes or T lymphocytes — is critically important because it strongly influences prognosis. B-cell lymphoma carries a significantly better prognosis than T-cell lymphoma, with median survival times roughly double those seen with T-cell disease in many studies.
Which Breeds Are Predisposed
Certain breeds show markedly higher rates of lymphoma than the general dog population. Golden Retrievers, Boxers, Bulldogs, Basset Hounds, Saint Bernards, Scottish Terriers, Airedales, and Labrador Retrievers all appear on lists of predisposed breeds across multiple studies. Middle-aged to older dogs are most commonly affected, though lymphoma can occur at any age. Interestingly, Boxers tend to develop T-cell lymphoma at higher rates, which partially explains why outcomes in this breed can be less favourable.
Recognising Lymphoma: What to Look For
The most common presentation of multicentric lymphoma is painless enlargement of the peripheral lymph nodes — most easily felt under the jaw, in front of the shoulder blades, in the armpits, in the groin, and behind the knees. Many owners first notice a lump under the jaw or notice that their dog's neck looks swollen.
Depending on the extent of disease, dogs may also show lethargy, reduced appetite, weight loss, increased thirst and urination (particularly if hypercalcaemia is present — a metabolic complication more common with T-cell disease), and general malaise. Some dogs appear essentially well at diagnosis, while others are clearly unwell.
Diagnosis and Staging
Diagnosis is typically confirmed through cytology — a fine-needle aspirate of an affected lymph node — or biopsy. Cytology is quick and minimally invasive, though biopsy provides more architectural information and may be preferable for certain lymphoma subtypes. Flow cytometry and PCR-based assays for antigen receptor rearrangement (PARR testing) are used to immunophenotype the tumour and confirm clonality.
Staging investigations include blood work, urinalysis, chest radiographs, abdominal ultrasound, and bone marrow evaluation. The World Health Organisation staging system for canine lymphoma ranges from Stage I (single lymph node involvement) to Stage V (bone marrow or blood involvement), with substage a indicating the dog appears clinically well and substage b indicating illness. Substage a consistently carries a better prognosis than substage b.
Treatment: Chemotherapy Protocols
Lymphoma is one of the most chemotherapy-responsive cancers in dogs, and treatment can produce meaningful remissions. The gold standard multi-agent protocol is CHOP-based chemotherapy, named after the drugs used: cyclophosphamide, doxorubicin (hydroxydaunorubicin), vincristine (Oncovin), and prednisolone. This is administered over a 19 to 25-week protocol and achieves complete remission in approximately 80 to 90% of dogs with B-cell disease.
Median survival for dogs treated with CHOP is roughly 12 to 14 months, with around 20 to 25% of dogs achieving two-year survival. For T-cell lymphoma, remission rates are lower and survival times are shorter, typically in the range of 6 to 9 months even with treatment.
Single-agent protocols using doxorubicin alone, or oral lomustine (CCNU) for cutaneous forms, are alternatives for owners unable to commit to the full multi-agent protocol. Prednisone alone can provide short-term palliation and temporary clinical improvement but does not extend survival and may compromise later chemotherapy response.
Side Effects and Quality of Life During Treatment
A genuine concern for many owners considering chemotherapy is whether treatment will make their dog feel terrible. Veterinary chemotherapy protocols are designed with quality of life as a primary consideration — doses are calibrated to achieve remission whilst minimising toxicity, rather than pushing to the maximum tolerated dose as is often the case in human oncology.
Most dogs tolerate CHOP reasonably well. The most common side effects include mild gastrointestinal upset (nausea, reduced appetite, loose stools) in the days following treatment, and transient immunosuppression around 7 to 10 days after certain drugs. Serious complications occur in a minority of patients and are managed by the oncology team with dose adjustments, supportive medications, and hospitalisation if required.
What Happens After Remission
Most dogs that achieve remission will eventually relapse, as lymphoma cells acquire resistance to the drugs used. Second-line rescue protocols — using different drug combinations — can achieve remission again in some patients, though these remissions are typically shorter than the first. Decisions about rescue therapy depend on how long the first remission lasted, the dog's overall condition, and owner preferences.
Regular rechecks throughout treatment and beyond are essential for catching relapse early and adjusting the management plan accordingly. Many owners find that the period of remission, during which their dog feels well and lives normally, is deeply valuable regardless of what follows.